RecruitingPhase 1NCT06730542
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Studying OBSOLETE: Lymphomatous meningitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Juan P. Alderuccio, MD
- Principal Investigator
- Juan P Alderuccio, MDUniversity of Miami
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- University of Miami, Miami, Florida, United States
Collaborators
BeiGene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06730542 on ClinicalTrials.gov